Biotechnology

Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

May 2, 2023 4:30 PM

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more

Abivax: Publication of an Expert Article in JCC on Obefazimod as Promising Therapeutic Management Option for UC Patients

May 2, 2023 12:25 PM

The authors of the expert article published in the Journal of Crohn's and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel Diseases The KOLs state that obefazimod is a first-in-class drug with a unique mechanism of action and with great promise in the therapeutic management of ulcerative colitis patients The experts expect that the results from the ongoing Phase 3 program with obefazimod in...

Read more

Imagene Wins Frost & Sullivan's Technology Innovation Leadership Award for Its Revolutionary AI-Based Molecular Testing for Cancer Diagnosis

May 2, 2023 9:00 AM

TEL AVIV, ISRAEL / ACCESSWIRE / May 2, 2023 / Imagene, an emerging leader in the field of AI-based precision oncology, is proud to announce its win of the Frost & Sullivan 2023 Europe Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis. Best Practices Award - Imagene Imagene won the 2023 Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis. Frost & Sullivan Best Practices...

Read more

Biophytis Strengthens its Management Team

May 2, 2023 2:20 AM

Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance Appointment of Nicolas Fellmann as Chief Financial Officer PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWORE / May 2, 2023 / Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with...

Read more

enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 1, 2023 8:00 AM

- Ended the quarter with $34.2 million in cash and investments with quarterly burn of $4.9 million - in line with Company projections - Cash expected to support operations through the end of 2024, including release of SAVVE topline data and TAVVE first-in-human study data IRVINE, CA / ACCESSWIRE / May 1, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of...

Read more

Biophytis Announces Receipt of Nasdaq Notice

April 28, 2023 5:30 PM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 28, 2023 / Biophytis SA (NasdaqCM:BPTS), (Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it has received written notification (the "Notification...

Read more

Resolutions at BioInvent’s Annual General Meeting 2023

April 27, 2023 11:45 AM

LUND, SWEDEN / ACCESSWIRE / April 27, 2023 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Erik Esveld as new Board member, to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program. The AGM voted in...

Read more

D2V Clinical: Raising the Bar for Early-Phase Oncology

April 27, 2023 9:00 AM

Pharma industry veterans focus on asset value creation for sponsors DURHAM, NC / ACCESSWIRE / April 27, 2023 / Dose2Value Clinical (D2V Clinical) is a full-service global CRO addressing the challenges of early-phase oncology studies faced by biotech companies. Founded by seasoned veterans from the industry and the FDA, D2V Clinical focuses on asset value creation for sponsors. The company offers vast knowledge and insight to expedite program...

Read more

Notice of Extra General Meeting in Biovica International AB

April 27, 2023 8:45 AM

UPPSALA, SE / ACCESSWIRE / April 27, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Wednesday 17 May 2023, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm. Right to attend the general meeting Shareholders wishing to attend the general meeting...

Read more

BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus

April 27, 2023 8:00 AM

RIDGEFIELD, CT / ACCESSWIRE / April 27, 2023 / BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim. It will aim for a better understanding of wound healing and fibrosis in diseases of high unmet need, such as non-alcoholic...

Read more

Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success

April 27, 2023 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / April 27, 2023 / Enzolytics, Inc. (OTC PINK:"ENZC" or the "Company") announces its continuing progress with the recently announced business combination between Enzolytics' operating subsidiaries, Biogenysis and Virogentics, and Sagaliam Acquisition Corp. ("Sagaliam"). In preparation for this ownership transition, Dr. Gaurav Chandra has been appointed the Chief Executive Officer and Chairman of Biogenysis....

Read more

Asia Green Biotechnology Corp. Announces Resignation of a Director and Provides Business Update

April 26, 2023 6:20 PM

CALGARY, AB / ACCESSWIRE / April 26, 2023 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA), announces that Dr. Daryl Hudson has resigned as a director of the Company. In addition, the Board of Directors of Asia Green has provided an update on the current activities of the Company, which include various developments in SE Asia, where its international efforts are centred, and in Canada, where the Company continues to...

Read more

BioInvent International AB: Interim Report January-March 2023

April 26, 2023 2:15 AM

LUND, SE / ACCESSWIRE / April 26, 2023 / BioInvent International (STO:BINV) "After the end of the quarter, we received very positive news in our BI-1206 project. We now have a fourth complete response in the ongoing Phase 1/2 trial with BI-1206 in combination with rituximab in non-Hodgkin's lymphoma. This adds to the previously reported three ongoing complete responses. All in all, this is very encouraging news for NHL patients." - Martin...

Read more

Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit

April 25, 2023 3:20 PM

GERMANTOWN, MD / ACCESSWIRE / April 25, 2023 / Seraxis Inc., a pre-clinical stage company with a best-in-class islet replacement therapy for insulin-dependent diabetes, today announced the presentation of results from an efficacy study of Synthetic Replacement Endocrine (SRE) pancreatic clusters. These data were presented by William Rust, PhD, Chief Executive Officer at Seraxis, as an oral podium presentation at the 4th International Pancreas...

Read more

Selux Diagnostics Receives FDA Clearance on Their Gram-Negative Panel, Expanding the Antibiotic Menu for Its Next Generation Phenotyping System for Rapid AST

April 24, 2023 12:15 PM

Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies. BOSTON, MA / ACCESSWIRE / April 24, 2023 / Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received its second 510(k) clearance on the Selux Next Generation Phenotyping (NGP) System from...

Read more

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study

April 24, 2023 9:00 AM

Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertension California-based InClin to provide CRO services to manage and expedite the study Lexaria is working with its regulatory and clinical advisors toward upcoming IND submission KELOWNA, BC / ACCESSWIRE / April 24, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global...

Read more

Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics

April 21, 2023 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / April 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced that the Company's representative traveled to Africa to arrange for the delivery of its ITV-1 immunotherapy treatments to African hospitals and to finalize the information to be included on product labels as required by the African regulatory...

Read more

Lexaria is Receiving Four New Patents

April 20, 2023 9:00 AM

KELOWNA, BC / ACCESSWIRE / April 20, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received notifications of four new patents either awarded or allowed. In Japan, Lexaria has received a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria's 5th awarded...

Read more

Edesa Biotech to Participate in Swiss Biotech Day

April 20, 2023 8:30 AM

TORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will join a Canadian delegation of officials and industry participating in Swiss Biotech Day on April 24-25, 2023 in Basel, Switzerland. Attendees who are interested in meeting with the company can utilize the conference scheduling system or...

Read more

This 4/20 is Different: New Roadside Cannabis Test to Be Piloted by Police Departments Across the U.S.

April 20, 2023 6:00 AM

NEW YORK, NY / ACCESSWIRE / April 20, 2023 / Neuro-diagnostic company Oculogica today announced the launch of OcuPro, the fastest roadside cannabis test with immediate results, along with pilots planned with several police departments across the U.S. Officers administer the 45-second long test and receive an immediate indication of recent cannabis use and impairment. The technology is based on studies of several hundred cannabis users which are...

Read more